Phibro Q3 net income falls 43% to $10.0M; Animal Health sales up 11%

PHIBRO ANIMAL HEALTH CORP

2023-Q3 EPS reported $0.52 revenue$722,840,000

Q3 net sales $245.7M (+3% YoY); net income $10.0M (-43%); diluted EPS $0.25 (-43%); adjusted diluted EPS $0.29 (-13%).
Animal Health segment net sales +11% to $164.4M; Mineral Nutrition -9% to $62.9M; Performance Products -17% to $18.3M.
Adjusted EBITDA $27.4M (-2% YoY); free cash flow -$43M trailing twelve months (inventory build of $43M).
Company reiterates FY2023 guidance: net sales $960M-$1B, adjusted diluted EPS $1.21-$1.31.
Management notes recessionary pressure in Mineral Nutrition; opened new autogenous vaccine facility in Brazil.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PHIBRO ANIMAL HEALTH CORP reported three months ended March 31, 2023 (compared to the three months ended March 31, 2022) results: revenue $245.7 million, net income $10.0 million, EPS diluted EPS of $0.25.

Period: three months ended March 31, 2023 (compared to the three months ended March 31, 2022)
Revenue: $245.7 million
Net income: $10.0 million
EPS: diluted EPS of $0.25
Result: reported results

Exact text from the filing

third quarter and year-to-date ended March 31, 2023. Highlights for the three months ended March 31, 2023 (compared to the three months ended March 31, 2022) - Net sales of $245.7 million, an increase of $6.1 million, or 3% - Net income of $10.0 million, a decrease of $7.6 million, or 43% - Diluted EPS of $0.25, a decrease of $0.19, or 43% - Adjusted EBITDA of

View on SEC.gov

Browse all earnings releases →

PHIBRO ANIMAL HEALTH CORP filing history →

Source: SEC EDGAR

accession 0001558370-23-007861

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.